Our Clinical Trial

Our malaria vaccine candidate VLPM01 clinical trial designed to evaluate the safety, tolerability, immunogenicity and experimental efficacy of VLPM01 in healthy, malaria-naïve adult volunteers.

The study will have four (4) phases: Screening, Dose Escalation, Controlled Human Malaria Infection (CHMI) and Follow-Up. The study will be conducted at the Walter Reed Army Institute of Research in Silver Spring, Maryland (WRAIR), as this institute has extensive experience in conducting clinical studies of malaria vaccines with CHMI. A total of 36 participants will be enrolled in this study. Thirty (30) eligible participants will participate in the Dose Escalation Phase as vaccinees and 6 eligible participants will be added during the CHMI Phase to act as infectivity controls.

For more information

Contact the WRAIR Clinical Trials Center Recruitment Office  Phone: 1-866-4-CTC-STUDY (866-428-2788).

Surface Antigen Display

i-αVLP Platform

Cancer Vaccine

Malaria Vaccine

Interior Gene Delivery

Replicon Platform

Cancer Therapy

Native Virus Modification

Native Virus Vaccines

Dengue Vaccine

Vaccines are one of the most important inventions in the past centuries. The successful vaccines save millions of lives by eradicating the epidemic and pandemic diseases. I left the research field and formed VLP Therapeutics because I am committed to developing the next generation vaccine technology to treat the diseases that currently lack effective treatment. We believe that our i-αVLP vaccine technology has a potential to create a breakthrough treatments and make significant contributions to the improvement of global public health.